Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

rphan GPCRs. These four orphans –  GPR65/TDAG8, GPR82, MRGE and MRGF – are linked to a series of important indications, including several types of cancer and inflammatory disorders, such as asthma (GPR65/TDAG8), appetite and body weight (GPR82) and pain (MRGE and MRGF). Omeros also recently announced its ability to unlock Class B orphan GPCRs.
  • Reported positive data from its second pivotal Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.  OMS302 met its co-primary endpoints by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period. Now with positive data from both trials in the OMS302 Phase 3 clinical program, Omeros plans to submit a New Drug Application with the U.S. Food and Drug Administration in the first half of 2013 and a Marketing Authorization Application with the European Medicines Agency in mid-2013. Omeros is building its marketing and sales capabilities in expectation of OMS302's planned commercial launch in 2014.
  • Announced promising data from the single-ascending-dose (SAD) study portion of its Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program for schizophrenia and cognitive disorders.  In this SAD study, OMS824 was well tolerated and demonstrated linear pharmacokinetics, a long half-life consistent with once daily dosing and good systemic exposure that resulted in the expected pharmacological effects in healthy subjects.  With these encouraging data, Omeros advanced OMS824 to the next stage of the Phase 1 clinical program – the evaluation of multiple-ascending dosing (MAD) of the compound.  Omeros expects to report data from this MAD trial in the near future. 
  • Completed the first Phase 3 clinical trial compar
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
    8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
    10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
    11. Celsion Corporation Announces $15 Million Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/25/2015)... March 25, 2015 Optimal Research, LLC has ... Excellence (ViE) Award "Best Clinical Site or Trial Network". ... Optimal has been selected as a nominee in this ... a "Highly Recommended" distinction in 2014. The ViE awards ... efforts, accomplishments, and positive contributions of companies and individuals ...
    (Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
    (Date:3/25/2015)... Md. , March 25, 2015 Accelovance, ... named a finalist for "Best Contract Research Organization" at ... the World Vaccine Congress. This is ... a finalist for the award, winning for "Best Contract ... a "Highly Recommended" distinction in 2013. "We,re ...
    (Date:3/25/2015)... UK (PRWEB) March 25, 2015 An ... natural ingredients in all forms of food nutrients, regulatory ... to a substantial rise in demand for natural astaxanthin ... have started to ramp up their capacities to satisfy ... both natural and synthetic source astaxanthin (used in nutraceuticals, ...
    Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
    ... Inc. , a software developer for off-road mapping applications, closed ... deal with Kegonsa Capital Partners that values the ... in funds that will enable it to furhter develop its ... vehicles - maps that are designed to interface with global ...
    ... looking for health information technology to have a moderating ... while longer, according to the head of an influential ... CEO of the Healthcare Information and Management Systems ... improving interoperability between facilities remain high IT priorities, but ...
    ... a trade owner have to purchase all relevant domain names ... does not register all the variations, are they free for ... defunct businesses? , ,These are questions posed by a ... on its own facts, the following principles can be used ...
    Cached Biology Technology:Wausau start up secures $560K for GPS maps 2Wausau start up secures $560K for GPS maps 3CEO of healthcare group still hopeful IT will save employers money 2CEO of healthcare group still hopeful IT will save employers money 3Is your business domain at risk? 2Is your business domain at risk? 3Is your business domain at risk? 4
    (Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
    (Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
    (Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
    ... notorious for their thick skin and well-armored bodies. So it comes ... touch is one of the most acute in the animal kingdom. ... of small, pigmented domes that dot their skin all over their ... jaws. A new study, published in the Nov. 8 issue ...
    ... 7, 2012 Listed below are the selected highlights for ... journal, GENETICS . The November issue is available ... , Vol. 192, November 2012, Copyright 2012. Please ... in these articles. ISSUE HIGHLIGHTS , An ...
    ... Every week in his clinic at the University of Michigan, ... dying or shrinking due to disease or injury. ... other effects that nerve-destroying conditions cause and wishes he ... regenerate their nerves. Then he heads to his research lab ...
    Cached Biology News:Despite their thick skins, alligators and crocodiles are surprisingly touchy 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 3Genetics Society of America's GENETICS journal highlights for November 2012 2Genetics Society of America's GENETICS journal highlights for November 2012 3Genetics Society of America's GENETICS journal highlights for November 2012 4Stem cells + nanofibers = Promising nerve research 2Stem cells + nanofibers = Promising nerve research 3
    Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
    Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
    Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
    ... - Red, 20X Immunogen ... at 20X concentration for use in ... Quality Assurance ... fluorescence polarization assays. ...
    Biology Products: